Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2021 16:01 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021

Recently demonstrated single-dose intravenous administration of a PATrOL™-enabled compound resolves the causal genetic defect in myotonic dystrophy type 1 (DM1) in transgenic animals; Company on...
January 28, 2021 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics

Acquisition includes intellectual property for peptide nucleic acid genetic medicine portfolio that has demonstrated in vivo activity in several disease indications Consolidates new peptide nucleic...
January 11, 2021 06:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of...
December 23, 2020 16:05 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020

Data presented throughout 2020 have validated the potential of the PATrOL™ platform to develop highly targeted therapies that increase, decrease or change causal protein function Plan to provide...
December 16, 2020 06:30 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL™-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1

In vivo data after single-dose IV administration demonstrate engagement with DMPK mRNA and broad rescue of mis-splicing across key transcripts Findings provide support for hypothesized mechanism of...
December 02, 2020 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer

PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...
November 23, 2020 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics to Participate in Upcoming Investor Conferences

PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of...
November 17, 2020 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board

PITTSBURGH, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...
November 10, 2020 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17

PITTSBURGH, Nov. 10, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of...
October 13, 2020 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board

PITTSBURGH, Oct. 13, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of...